NCT04237090View on ClinicalTrials.gov

Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel

PHASE3CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 14, 2020

Primary Completion Date

August 28, 2020

Study Completion Date

September 4, 2020

Conditions
Breast CancerLung CancerOvarian CancerOesophageal CancerHead Cancer NeckCervical CancerEndometrial Cancer
Interventions
DRUG

Diphenhydramine

Drug identification number : 02369567

DRUG

Cetirizine

Drug identification number : 02231603

DRUG

Lactose pill

Natural product number : 00501190

DRUG

Sodium chloride 0.9%

Drug identification number : 00037796

Trial Locations (1)

H1T 2M4

CIUSSS de l'Est-de-l'île-de-Montréal, Montreal

All Listed Sponsors
lead

Ciusss de L'Est de l'Île de Montréal

OTHER

NCT04237090 - Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel | Biotech Hunter | Biotech Hunter